Skip to main content

Table 3 Association of SRF and two-grade macular HEs aggravation at one month in both groups

From: Aggravation of retinal hard exudates after intravitreal anti-vascular endothelial growth factor therapy for cystoid macular edema and the risk factors: a retrospective study

  Disease n HEs aggravation eyes HEs non-aggravation eyes P-value
CME without SRF DR 69 17 (24.6%) 52 (75.3%) 0.087
BRVO 78 10 (12.8%) 68 (87.1%)
CME with SRF DR 77 34 (44.1%) 43 (55.8%) 0.010*
BRVO 64 15 (23.4%) 49 (76.5%)
Total 288 76 (26.3%) 212 (73.7%)  
CME without SRF 147 27 (18.3%) 120 (81.6%) 0.001*
CME with SRF 141 49 (34.7%) 92 (65.2%)
  1. HE Hard exudate, CME Cystoid macular edema, SRF Subretinal fluid. *, p < 0.05 by chi-square test